320 related articles for article (PubMed ID: 34430373)
1. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
Belluomini L; Dodi A; Caldart A; Kadrija D; Sposito M; Casali M; Sartori G; Ferrara MG; Avancini A; Bria E; Menis J; Milella M; Pilotto S
Transl Lung Cancer Res; 2021 Jul; 10(7):3369-3384. PubMed ID: 34430373
[TBL] [Abstract][Full Text] [Related]
2. Oligoprogression in non-small cell lung cancer: a narrative review.
Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
[TBL] [Abstract][Full Text] [Related]
3. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
4. Local control strategies for management of NSCLC with oligoprogressive disease.
Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
[TBL] [Abstract][Full Text] [Related]
5. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
6. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
7. Oligoprogression in Non-Small Cell Lung Cancer.
Harada D; Takigawa N
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830977
[TBL] [Abstract][Full Text] [Related]
8. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
9. The current state of oligometastatic and oligoprogressive non-small cell lung cancer.
Tumati V; Iyengar P
J Thorac Dis; 2018 Aug; 10(Suppl 21):S2537-S2544. PubMed ID: 30206497
[TBL] [Abstract][Full Text] [Related]
10. Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
Peeters STH; Van Limbergen EJ; Hendriks LEL; De Ruysscher D
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925139
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
12. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Ng TL; Morgan RL; Patil T; Barón AE; Smith DE; Ross Camidge D
Lung Cancer; 2018 Dec; 126():112-118. PubMed ID: 30527174
[TBL] [Abstract][Full Text] [Related]
13. Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma.
Yang G; Kim KH; Lee CG; Hong MH; Kim HR; Cho Y; Yoon HI
Cancer Res Treat; 2024 Jan; 56(1):115-124. PubMed ID: 37641819
[TBL] [Abstract][Full Text] [Related]
14. Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.
Jongbloed M; Khosla AA; Bartolomeo V; Jatwani K; Singh R; De Ruysscher DKM; Hendriks LEL; Desai A
Curr Oncol Rep; 2024 Jan; 26(1):80-89. PubMed ID: 38175464
[TBL] [Abstract][Full Text] [Related]
15. Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review.
Tjong MC; Louie AV; Iyengar P; Solomon BJ; Palma DA; Siva S
Transl Lung Cancer Res; 2021 Jul; 10(7):3446-3456. PubMed ID: 34430379
[TBL] [Abstract][Full Text] [Related]
16. Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer.
West H
Clin Chest Med; 2020 Jun; 41(2):249-258. PubMed ID: 32402360
[TBL] [Abstract][Full Text] [Related]
17. Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies-a narrative review.
Fallet V; Matton L; Schernberg A; Canellas A; Cornelis FH; Cadranel J
Transl Lung Cancer Res; 2021 Jul; 10(7):3457-3472. PubMed ID: 34430380
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T; Kenmotsu H; Harada H; Ohde Y; Chiba Y; Haratani K; Okimoto T; Sakamoto T; Wakuda K; Ito K; Uemura T; Sakata S; Kogure Y; Nishimura Y; Nakagawa K; Yamamoto N
BMC Cancer; 2021 Oct; 21(1):1121. PubMed ID: 34663250
[TBL] [Abstract][Full Text] [Related]
19. Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Santos PMG; Li X; Gomez DR
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010969
[TBL] [Abstract][Full Text] [Related]
20. How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.
Remon J; Menis J; Levy A; De Ruysscher DKM; Hendriks LEL
Transl Lung Cancer Res; 2021 Jul; 10(7):3486-3502. PubMed ID: 34430382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
